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Abstract 
Protein homeostasis (proteostasis) is essential for maintaining the functionality of the 
proteome. The disruption of proteostasis, due to genetic mutations or an age-related decline, 
leads to aberrantly folded proteins that typically lose their function. The accumulation of 
misfolded and aggregated protein is also cytotoxic and has been implicated in the 
pathogenesis of neurodegenerative diseases. Neurons have developed an intrinsic protein 
quality control network, of which molecular chaperones are an essential component. 
Molecular chaperones function to promote efficient folding and target misfolded proteins for 
refolding or degradation. Increasing molecular chaperone expression can suppress protein 
aggregation and toxicity in numerous models of neurodegenerative disease; therefore, 
molecular chaperones are considered exciting therapeutic targets. Furthermore, mutations in 
several chaperones cause inherited neurodegenerative diseases. In this review, we focus on 
the importance of molecular chaperones in neurodegenerative diseases, and discuss the 
advances in understanding their protective mechanisms. 
 
Introduction 
Proteins must fold to their native state in order to achieve functionality. However, in the 
crowded cellular environment, and under environmental and physiological stress conditions 
such as heat, oxidative stress and inflammation, proteins are susceptible to the formation of 
non-native interactions that can lead to protein misfolding and aggregation. The 
accumulation of misfolded and aggregated protein is considered toxic to the cell and is 
implicated in numerous diseases such as type 2 diabetes, cardiovascular disease and 
neurodegenerative diseases. Cells have therefore developed an intrinsic network of protein 
quality control machinery that functions to balance protein folding, misfolding, aggregation 
and degradation, thereby maintaining protein homeostasis (proteostasis) and the 
functionality of the proteome. The protein quality control machinery includes molecular 
chaperones, which act as the first line of defence and participate in the refolding or, 
alternatively, the degradation of misfolded proteins. Their role in maintaining proteostasis in 
neurons, which are post-mitotic cells that are particularly vulnerable to protein aggregation, 
is the subject of this review.  
Molecular chaperones 
Molecular chaperones are defined as proteins that interact with, stabilise or assist another 
protein to gain its native and functionally active conformation, without being present in the 
final structure [1]. Members of the molecular chaperone family are often referred to as heat-
shock proteins (Hsps) due to their upregulation under stress conditions that typically 
destabilise proteins, such as elevated temperature and oxidative stress. Molecular 
chaperones are often classified according to their molecular weight and members include 
Hsp90, Hsp70, Hsp60, Hsp40 (DnaJ) and the small Hsps. Molecular chaperones display 
large functional diversity and in addition to their fundamental roles in de novo folding, and 
the refolding of misfolded protein, chaperones also regulate critical cellular processes such 
as protein trafficking, protein degradation and macromolecular complex assembly [2]. 
Hsp90 (HSPC) family 
Hsp90 is an ATP-dependent chaperone that functions in the activation and stabilisation of 
client proteins; including protein kinases, cell cycle regulators, cell surface receptors and 
transcription factors. Therefore, Hsp90 plays a critical role in cellular processes including 
signal transduction, cell cycle progression, apoptosis and protein degradation [3]. The 
activation of Hsp90 clients is driven by a cycle of substrate binding and release mediated by 
a series of conformational changes in the chaperone and an ATP-induced transition between 
an open and a closed conformation. Hsp90 exists as a homodimer, with each subunit 
consisting of three domains; an N-terminal ATP-binding domain (N-domain), a middle 
domain that binds the substrate (M-domain) and a C-terminal dimerisation domain (C-
domain). In the absence of nucleotide Hsp90 adopts a V-shaped open conformation. The 
binding of ATP to the N-domain induces a conformational change that closes a lid over the 
nucleotide binding pocket. Following lid closure, the N-domains dimerise, forming a compact 
structure with a closed conformation. The formation of the closed dimer induces ATP 
hydrolysis, subsequently promoting the N-domains to dissociate and the return of Hsp90 to 
the open conformation, with the release of the substrate [4]. 
The reaction cycle of Hsp90 is regulated by various co-chaperones. The co-chaperones 
exhibit specific binding preferences for different Hsp90 conformations and affect different 
stages of the cycle, such as client binding and ATP hydrolysis. Co-chaperones therefore 
usually co-operate in a sequential cycle to facilitate the maturation of Hsp90 clients.  
Hsp70 (HSPA) family 
Hsp70 functions in a wide array of cellular processes including the folding of newly 
synthesised protein, the refolding of misfolded and aggregated protein, transport of proteins 
across membranes, and protein degradation [3]. These functions rely on the ability of Hsp70 
to interact with hydrophobic stretches exposed in client proteins and subsequently undergo 
an ATP-dependent cycle of substrate binding and release. Hsp70 is composed of a N-
terminal ATPase domain (NBD) and a C-terminal substrate binding domain (SBD), divided 
into subdomains that form a hydrophobic binding pocket and a lid [2]. The NBD and SBD are 
connected by a flexible linker that enables the NBD to allosterically control the conformation 
of the SBD. In the ATP-bound state the binding pocket and lid are in an open conformation. 
The SBD has a low substrate affinity and fast substrate exchange rates. The hydrolysis of 
ATP to ADP drives the SBD into a high affinity state for substrate binding through the closing 
of the lid, enabling stable binding of the client protein. The release of ADP and the rebinding 
of ATP triggers the opening of the lid and the subsequent unloading of the bound substrate. 
The Hsp70 reaction cycle contains two rate limiting steps, ATP hydrolysis, due to low basal 
ATPase activity, and ADP dissociation, due to the high levels of cytoplasmic ATP under 
physiological conditions. Therefore, Hsp70 requires the action of co-chaperones to facilitate 
the reaction cycle between ATP and ADP bound states. The ATPase activity of Hsp70 is 
stimulated by members of the DnaJ (Hsp40) family via their conserved J domain [5]. The 
dissociation of ADP requires the opening of the nucleotide binding cleft, a process catalysed 
by a range of nucleotide exchange factors (NEFs), including the Hsp70-like Hsp110 proteins, 
HspBP1, SIL1 and BAG family [6].  
DnaJ (Hsp40) family 
As mentioned above, members of the DnaJ family (also referred to as Hsp40) are important 
regulators of Hsp70 activity by stimulating ATP hydrolysis. All DnaJ proteins contain a J 
domain, a conserved region of 70 amino acids that folds into four α-helices. Helix II and helix 
III form an antiparallel two-helix bundle, with a loop connecting the two helices containing a 
histidine-proline-aspartate (HPD) motif. The HPD motif is critical for lowering the activation 
energy of ATP hydrolysis [7].  
The human genome encodes 49 DnaJ proteins, which can be divided into three classes 
according to their domain composition [8]. Class I (DNAJA) proteins share all domains 
present in the Escherichia coli DnaJ protein, with an N-terminal J domain, a glycine-
phenylalanine (GF) rich region, a zinc binding domain and a C-terminal domain. Class II 
(DNAJB) proteins contain an N-terminal J domain and a GF rich region, whereas class III 
(DNAJC) proteins share only the J domain. The diversification of domains outside the J 
domain has enabled DnaJ proteins to adopt specialised functions. For example, domains 
that target DnaJ proteins to precise intracellular locations to promote the interaction of 
Hsp70 with specific clients. Furthermore, client binding domains enable some DnaJ proteins 
to deliver clients to the SBD of Hsp70. Specialised domains also facilitate the targeting of 
clients for degradation, thus providing an important link between Hsp70, misfolded proteins 
and degradation [7,8]. 
 
 
Hsp60 (HSPD/E and CCT) family 
Hsp60, also called chaperonins, are large double ring complexes that enclose a central 
cavity. Substrate proteins, typically folding intermediates, are encapsulated in the central 
cavity, thereby shielding exposed hydrophobic residues from aggregation and allowing the 
substrate to fold in a protected environment. Chaperonins can be divided to two subgroups. 
Group I (HSPD) chaperonins are present in bacteria (GroEL) and the mitochondrial matrix 
(Hsp60). They contain 7 subunits per ring and require co-chaperones (HSPE) that act as lids 
over the complex (GroES in bacteria and Hsp10 in mitochondria). Group II chaperonins are 
found in archaea (thermosome) and in the cytosol of eukaryotes (CCT or TRiC). They 
typically have 8 subunits per ring and do not require co-chaperones. 
The GroEL-GroES chaperonin in E. coli has been the most extensively studied [9]. Each 
subunit consists of an equatorial ATP binding domain, a hinge domain and an apical 
substrate binding domain. The apical domain forms the entrance to the GroEL cavity and 
exposes hydrophobic residues to mediate substrate binding. Following substrate binding to 
one of the rings, ATP binds to each of the 7 subunits, inducing conformational changes, 
enabling the association of GroES and the subsequent encapsulation of the substrate. Upon 
GroES binding, the GroEL cavity enlarges, creating an environment for productive protein 
folding. The hydrolysis of ATP to ADP triggers the dissociation of the GroES lid and the 
release of the substrate. Multiple folding cycles may be required before the substrate 
reaches its native state [2]. 
Small HSP (HSPB) family 
Small heat shock proteins differ from the other major molecular chaperones in that they are 
ATP independent. The human genome encodes 10 small Hsps and they range in size from 
12-42 kDa. They share a conserved 100 amino acid α-crystallin domain that is flanked by 
variable N-terminal and C-terminal extensions. These extensions mediate substrate 
recognition as well as enabling the formation of oligomers. Small Hsps are able to bind to 
unfolded or misfolded protein and prevent their aggregation until the protein can be 
transferred to other cellular systems, such as the Hsp70-Hsp40 system [10]. 
Protein aggregates are a hallmark of neurodegenerative diseases 
Neurodegenerative diseases are caused by the progressive degeneration of neurons in the 
brain, eye and spinal cord. The loss of specific populations of neurons defines each disease 
and ultimately determines the clinical manifestations of the disease. The diseases can 
present as sporadic or familial, which typically share common symptoms and disease 
progression, thus the modes of neuronal dysfunction and death are likely to be similar in the 
sporadic and inherited cases.   
A pathological hallmark of many neurodegenerative diseases is the presence of 
ubiquitylated protein aggregates, indicating disturbances in proteostasis. Indeed, many of 
the causative mutations identified in familial cases lead to the misfolding and aggregation of 
the disease-related protein, for example, superoxide dismutase 1 (SOD1) in amyotrophic 
lateral sclerosis (ALS), huntingtin in Huntington’s disease (HD), α-synuclein in Parkinson’s 
disease (PD), amyloid beta (Aβ) in Alzheimer’s disease (AD), and tau in FTDP-17. Aging is 
considered the most significant risk factor for sporadic cases of ALS, AD and PD. It is well 
established that aging results in a decline in the efficiency of the protein quality control 
machinery [11], although the cause for this decline is currently unknown. The age-associated 
decline in protein quality control has been suggested to lead to an imbalance in the 
production of misfolded protein, which slowly overwhelms the protective capacity of the 
molecular chaperone machinery, ultimately leading to a vicious cycle which results in the 
collapse of proteostasis and causes neurodegeneration [2].  
The microscopically visible inclusions seen pathologically are thought to represent the end 
point of the protein aggregation process, which begins with the formation of small oligomers, 
protofibrils and mature fibrils. The exact species that exerts cytotoxicity is unknown; 
however, accumulating evidence suggests that soluble oligomers and protofibrils pose the 
most toxic potential to the cell. In support of this hypothesis, in vivo studies have shown that 
the injection of rats with soluble oligomers of α-synuclein or Aβ showed increased neuronal 
loss compared to rats injected with fibril forms of the proteins [12,13]. The formation of large 
aggregates is thought to be a protective defence mechanism adopted by the cell in order to 
sequester the toxic oligomers and protofibrils and prevent their interaction with other 
proteins. Although not considered the most toxic entity, large aggregates are still likely to 
contribute to cytotoxicity and disease progression in neurons due to their ability to recruit 
other proteins and physically obstruct axonal transport and other cellular processes. 
Neurons are highly polarised cells and rely heavily on axonal transport between the cell body 
and the synaptic terminal in order to effectively sustain their function. Neurons are therefore 
vulnerable to protein aggregation and thus place a high demand on the molecular chaperone 
machinery in order to maintain proteostasis. 
The upregulation of molecular chaperones is neuroprotective 
Considering the protective nature of molecular chaperones, their upregulation is a promising 
therapeutic approach to combat the progression of neurodegenerative disease. Proof of 
principle studies have suggested this is a potential strategy for the treatment of many 
neurodegenerative diseases by increasing the expression of individual chaperones (Table 1) 
or groups of chaperones (Table 2). Some of these studies are discussed in detail below.  
PD 
PD is caused by the progressive loss of dopaminergic neurons in the substantia pars 
compacta. The disease affects around 1% of the population aged 65 or over and is 
characterised by bradykinesia, rigidity and tremor [14]. A pathological hallmark of PD is the 
presence of intracellular protein aggregates called Lewy bodies that are primarily composed 
of ubiquitylated α-synuclein [15]. Hsp70 is the most widely studied molecular chaperone in 
relation to α-synuclein aggregation, and the overexpression of Hsp70 has been shown to 
regulate α-synuclein aggregation both in vitro and in vivo (Table 1). In a cell culture model, 
the overexpression of Hsp70 reduced high molecular weight and detergent insoluble α-
synuclein, as well as reducing total α-synuclein levels. This corresponded with a reduction in 
α-synuclein-induced toxicity [16]. Consistent with these findings, the expression of Hsp70 in 
an α-synuclein transgenic mouse model was also able to reduce high molecular weight and 
detergent insoluble species [16]. Further in vivo studies in both Drosophila melanogaster and 
mice showed that the Hsp70-mediated reduction in α-synuclein aggregation corresponded 
with an increase in dopaminergic neuron survival, enabling the preservation of striatal 
dopamine levels [17,18]. The mechanism by which Hsp70 suppresses α-synuclein 
aggregation is proposed to rely on the inhibition of fibril formation. Huang et al. (2006) 
showed that Hsp70 retarded the formation of α-synuclein prefibrils by binding to these 
species to inhibit nuclei formation [19]. Furthermore, Hsp70 was also found to bind to nuclei 
already present on the prefibrils to prevent their elongation.  
AD 
AD is the most common neurodegenerative disease, affecting over 500,000 people in the 
UK. The disease primarily affects the hippocampus and cerebral cortex regions of the brain, 
causing impairments in memory, cognitive function and difficulties with language. AD is 
characterised by the presence of extracellular Aβ plaques and intracellular neurofibrillary 
tangles of hyperphosphorylated tau. Several chaperones have been shown to modulate Aβ 
aggregation in vitro. Both αβ-crystallin (HSPB5), a member of the small Hsp family, and 
DnaJB6 bind to Aβ fibrils, inhibiting their elongation and growth [20,21]. Hsp70, Hsp40 and 
Hsp90 have also been shown to interact with Aβ peptides, this time acting on Aβ oligomers 
[22]. Recombinant Hsp70/Hsp40 and Hsp90 significantly slowed the rate of Aβ aggregation, 
re-directing Aβ into soluble circular structures instead of forming fibrils. However, Hsp70/40 
or Hsp90 had little effect on aggregation when added to pre-formed Aβ oligomers or fibrils. 
Only the combination of all three chaperones was able to significantly alter the structure of 
pre-formed oligomers. The data supported the concept that the upregulation of a 
combination of chaperones, rather than individual chaperones, may be more effective in 
combating Aβ aggregation (Table 2). This concept has been explored through the use of the 
Hsp90 inhibitor, 17-AAG, which activates the transcription factor HSF1, promoting the 
expression of a range of chaperones including Hsp70, Hsp40 and Hsp60. The upregulation 
of these chaperones protected neurons against Aβ toxicity both in vitro and in vivo. In 
neuronal cultures, 17-AAG restored Aβ-induced damage to dendritic structures [23]. 
Consistent with the in vitro data, the treatment of mice with 17-AAG protected neurons 
against Aβ-induced synaptic damage, enhancing long term potentiation and leading to an 
improvement in memory function [23].  
Hsp90 inhibition also protects against tau aggregation (Table 2). Tau is a client of Hsp90, 
binding via its aggregation prone microtubule binding repeat region [24]. The inhibition of 
Hsp90 prevents the stabilisation and maturation of tau, resulting in its degradation. In vitro 
studies have demonstrated that Hsp90 inhibition reduces the steady state levels of tau in 
addition to decreasing the levels of insoluble aggregated tau [25,26]. The reduction in tau 
aggregation was abolished in the presence of MG132, confirming that Hsp90 inhibition 
facilitates the proteasomal degradation of tau [27]. These findings were confirmed in vivo, 
with 17-AAG treatment reducing insoluble and hyperphoshorylated tau in a mouse model of 
tauopathy [27]. 
HD and polyQ diseases 
HD is an autosomal dominant, genetic disease that leads to progressive degeneration in the 
striatum and cortex of the brain, resulting in impairments in motor, cognitive and psychiatric 
abilities. HD is caused by the expansion of a CAG triplet repeat region in the gene 
Huntingtin. The translated protein contains a long stretch of polyglutamines (polyQ), driving 
huntingtin aggregation. Other CAG expansion diseases also have aggregation prone polyQ 
expanded polypeptides and show similarities in disease pathogenesis. 
The first ever report that molecular chaperones could act as potent modulators of protein 
aggregation in neurodegeneration was demonstrated by Cummings et al. (1998) in a cellular 
model of polyQ disease [28]. The overexpression of the DnaJ protein, DnaJA1, reduced the 
aggregation of polyglutamine expanded ataxin-1. Since this report the role of molecular 
chaperones in polyQ diseases has been extensively studied. Hsp70 and DnaJ proteins have 
been shown to suppress polyQ aggregation both in cells and in Drosophila. The expression 
of Hsp70 and DnaJB1 reduced the assembly of detergent insoluble polyQ fibrils, whilst 
increasing the formation of detergent soluble aggregates [29,30]. However, these results did 
not translate to a R6/2 mouse model of HD; Hsp70 overexpression had no significant effect 
on disease progression [31]. Increasing evidence suggests that DnaJ proteins and small 
Hsps are more potent suppressors of polyQ aggregation than Hsp70. Four members of the 
small Hsp family, HSPB6, HSPB7, HSPB8 and HSPB9, were found to significantly reduce 
polyQ aggregation in vitro [32]. Their protective effect was linked to stimulating the clearance 
of polyQ aggregates via the UPS or autophagy. For example, Hsp22 (HSPB8) forms a 
complex with Hsp70 and its co-chaperone Bag3 [33]. Bag3 interacts with the 
autophagosome receptor p62 [34], enabling the recruitment of Hsp70-Hsp22-Bag3 bound 
cargo into the autophagosome for degradation. The protective effect of Hsp22 
overexpression was suppressed in cells in which Bag3 had been reduced, or alternatively 
where autophagy was inhibited, implying that Hsp22 reduces neurotoxicity by targeting 
polyQ for autophagy-mediated degradation [33]. 
In the case of DnaJ proteins, a subfamily of Type II DnaJ proteins, including DnaJB2, 
DnaJB6 and DnaJB8, appear to be particularly effective at suppressing polyQ aggregation 
[35]. The overexpression of the neuronal DnaJ protein HSJ1 (DnaJB2) counteracts polyQ 
aggregation both in vitro and in vivo (Fig. 1). HSJ1 contains an N-terminal J domain, a client 
binding domain and two ubiquitin interacting motifs (UIMs) [36,37]. The combination of these 
domains enables HSJ1 to target some client proteins for proteasomal degradation. HSJ1 is 
alternatively spliced to produce two isoforms, HSJ1a and HSJ1b, with distinct intracellular 
localisations mediated by the C-terminal prenylation of the longer HSJ1b isoform [38]. Only 
the cytosolic and nuclear HSJ1a isoform was able to significantly reduce aggregation in a 
cellular model expressing polyQ huntingtin, highlighting that the localisation of chaperones is 
critical for their protective function [37]. The overexpression of HSJ1a was also shown to be 
neuroprotective in a R6/2 mouse model of HD [39]. HSJ1a expression significantly reduced 
the aggregation of mutant huntingtin in brain, whilst increasing the level of soluble protein. 
The mechanism of action was dependent on the association of HSJ1a with K63 
ubiquitylated, higher order, detergent insoluble species preventing their ability to nucleate 
further aggregation (Fig. 1). These changes led to an improvement in neurological 
performance of the R6/2 mice at a late stage of the disease. 
ALS 
ALS is the most common form of motor neuron disease, affecting around 2 in every 100,000 
in the UK. The disease is caused by the progressive loss of upper and lower motor neurons 
in the brain, the brainstem and the spinal cord, and is characterised by muscle weakness 
and atrophy leading to progressive paralysis. Around 20% of familial cases of ALS are 
caused by mutations in SOD1. Transgenic mice expressing mutant SOD1 develop an ALS-
like phenotype, characterised by intracellular SOD1 aggregates, and is the most widely used 
model to study ALS. 
The protective effects of Hsp27 (HSPB1) have been investigated in both cell and animal 
models of ALS. The overexpression of Hsp27 in neuronal cells stably expressing either 
SOD1 G93A or G93R had a protective effect against mutant SOD1-induced cell death [40]. 
Interestingly, this anti-apoptotic effect was enhanced by the overexpression of Hsp70 in 
conjunction with Hsp27 [40]. In vitro studies suggest that Hsp27 directly interacts with mutant 
SOD1, reducing aggregation by inhibiting fibril elongation, rather than by inhibiting the 
formation of fibril nuclei [41]. However, it is argued that, in addition to its chaperone function, 
the protective effect of Hsp27 may also be attributed to its roles in negatively regulating 
apoptosis and maintaining redox homeostasis. This is supported by in vitro studies on 
primary motor neuron cultures that show the overexpression of Hsp27 makes the cells more 
resistant to pro-apoptotic and oxidative insults [42]. Unfortunately, the role of Hsp27 in these 
two processes remains poorly characterised so the exact mechanism by which Hsp27 
reduces neurotoxicity is not clear. In vivo, the overexpression of Hsp27 protected motor 
neurons from cell death induced by nerve crush [43]. Furthermore, transgenic mice 
overexpressing Hsp27 and SOD1G93A showed an improvement in muscle force, reflected by 
an increase in motor unit numbers and an increase in motor neuron survival in the spinal 
cord [44]. However, these improvements were only evident at an early stage of the disease 
and were not sustained over the long term.  
In contrast to Hsp27, the overexpression of HSJ1a was able to ameliorate late stage disease 
in a SOD1G93A mouse model [45]. Overexpression of HSJ1a led to a significant improvement 
in neuromuscular function, with a preservation of muscle force, an increase in motor unit 
number and enhanced motor neuron survival. HSJ1a was present in a complex of SOD1G93A 
and reduced its aggregation at late stages of the disease. In a cell model, HSJ1a stimulated 
SOD1G93A ubiquitylation and proteasomal degradation in a J domain and UIM dependent 
manner (Fig. 1). Altered ubiquitin immunoreactivity was observed in the double transgenic 
mice, suggesting this process may also be occurring in vivo.  
Overall the genetic manipulation of molecular chaperones, in particular Hsp70 and Hsp27, 
has shown limited success in combating ALS disease progression in vivo. However, a 
different approach that utilises pharmacological agents to modulate the proteostasis 
network, rather than just one specific chaperone, was more effective in targeting protein 
aggregation and restoring proteostasis (Table 2).  Arimoclomol, a hydroxylamine derivate, 
amplifies Hsp expression by stabilising the binding of HSF1 to heat shock elements, leading 
to the upregulation of chaperones including Hsp90, Hsp70 and Hsp60. The treatment of 
SOD1G93A mice with arimoclomol at pre-symptomatic or early symptomatic stages of the 
disease delayed disease progression, with a decrease in ubiquitin positive aggregates in the 
spinal cord and an improvement in muscle function and motor neuron survival at late stages 
of the disease [46]. This was accompanied by a 22% increase in lifespan. In addition to 
potentiating the heat shock response, arimoclomol can also enhance the unfolded protein 
response, potentially expanding the range of applicable diseases [47]. 
Mutations in molecular chaperones cause neurodegenerative disease 
The importance of molecular chaperones in maintaining neuronal proteostasis is further 
highlighted by the identification of mutations in molecular chaperones in familial cases of 
neurodegenerative disease (Table 3). Interestingly, mutations have been identified in 
chaperones that are also protective against neurotoxicity when overexpressed in models of 
disease, such as HSJ1, Hsp22 and Hsp27.  
 
HSJ1 (DnaJB2) 
Distal hereditary motor neuropathies (dHMN) are a clinically and genetically heterogeneous 
group of disorders caused by the progressive degeneration of the lower motor neurons in the 
spinal cord. The disease is characterised by muscle weakness and atrophy of the lower 
limbs. Symptom onset typically occurs in the first two decades of life, and patients typically 
present with gait abnormalities, paralysis of foot and toe extension and lack of ankle and 
knee-jerk reflexes. In 2012, Blumen et al. reported mutations in HSJ1 in a consanguineous 
Moroccan family with dHMN [48]. Recently, a second mutation was identified in a Turkish 
family also with dHMN [49]. Both mutations are homozygous and are located at donor splice 
sites, leading to the loss of HSJ1 protein expression. A third mutation in HSJ1 has also been 
identified recently, this time in a family with Charcot-Marie-Tooth type 2 (CMT2) [49]. CMT2 
closely resembles dHMN but patients have sensory abnormalities in addition to motor 
involvement. The mutation is a substitution of a tyrosine for a cysteine at reside 5 (Y5C). 
Residue 5 of HSJ1 is located in the J domain and is highly conserved in HSJ1 orthologs 
across multiple species. Our lab has confirmed the pathogenicity of the HSJ1 Y5C mutation 
(Heather Smith, unpublished observations). All three mutations identified thus far lead to a 
loss of HSJ1 function, suggesting that HSJ1 is important for motor neuron survival. Further 
investigations are required to reveal how the loss of HSJ1 chaperone function leads to motor 
neuron degeneration.  
 
Hsp27 (HSPB1) and Hsp22 (HSPB8) 
Mutations in Hsp27 (HSPB1) and Hsp22 (HSPB8) have been reported in families with both 
dHMN and CMT2. 16 mutations in Hsp27 have been identified to date and the majority of 
mutations identified are missense mutations in the α-crystallin domain [50-57]. The 
mutations share the common property of inducing protein instability and aggregation. All 
mutations reported, apart from one, were inherited in an autosomal dominant manner. The 
dominant inheritance might result from a gain of toxic function, but it is also likely that the 
loss of chaperone function contributes to the disease mechanism, possibly through dominant 
negative effects on chaperone oligomers. In addition to their chaperone function, some 
HSPB proteins can modulate the dynamics of the cytoskeleton by regulating the stabilisation 
of microtubules and intermediate filaments. Investigations suggest that this regulatory 
function is impaired in Hsp27 mutants. The expression of mutant Hsp27 in cells was found to 
result in the sequestration of intermediate filaments into Hsp27 aggregates, leading to the 
destabilisation of the cytoskeletal network [50,58]. Furthermore, transgenic mice expressing 
either Hsp27 S135F or P182L exhibit impaired axonal transport of mitochondria, with the 
mice developing a distal motor neuropathy [59]. The evidence therefore suggests that 
Hsp27-mediated disruption of axonal transport is an important underlying mechanism of 
motor neuron degeneration. 
Two mutations in Hsp22 have been identified in five separate families with dominant 
inheritance. The mutations (K141E and K141N) affect lysine residue 141 in the α-crystallin 
domain and cause aggregation [57]. Interestingly, when expressed in cells, mutant Hsp22 
was found to sequester Hsp27 in its aggregates [57]. The loss of Hsp27 may contribute to 
the degeneration process. It has also been proposed that mutations in Hsp22 cause motor 
neuron death due to dysfunctions in the removal of misfolded proteins by autophagy [33], a 
reduction in the ability to remove misfolded protein could be a critical determinant in 
neuronal toxicity. 
Sacsin 
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is an early onset 
recessive neurodegenerative disease caused by the progressive loss of Purkinje cells in the 
cerebellum, followed by motor neurons in the spinal cord [60]. The disease is caused by 
mutations in the DnaJ protein sacsin (DnaJC29), with over 170 mutations identified 
throughout the 520 kDa protein. Sacsin is composed of a N-terminal ubiquitin-like domain 
that binds to the proteasome [61], followed by three large sacsin repeat regions, suggested 
to have Hsp90-like chaperone function [62,63], a XPCB domain that binds to protein ligases 
[64], a C-terminal J domain and a HEPN domain that mediates sacsin dimerisation 
[61,62,65]. The combination of these domains implies a role in protein quality control. The 
mutations identified are proposed to lead to loss of sacsin function, however, a full 
understanding of sacsin function is currently lacking. Sacsin is predominantly localised in the 
cytoplasm but also shows localisation to the mitochondria. Sacsin interacts with dynamin-
related protein 1 (DRP1), a GTPase that mediates mitochondrial fission [66]. Interestingly, in 
both patient fibroblasts and a sacsin knockout mouse, the mitochondria appear overly fused 
and show a reduction in mobility [66]. This suggests that sacsin may participate, either 
directly or indirectly, in mitochondrial fission. Mitochondrial dysfunction is a common feature 
in many neurodegenerative diseases and is likely to be a key mechanism underlying 
ARSACS. 
 
 
Conclusions 
Neurodegenerative diseases are characterised by disturbances in neuronal proteostasis 
caused by genetic mutations or alternatively an age-related decline in the proteostasis 
network. The upregulation of molecular chaperones has been demonstrated to suppress the 
neurotoxicity associated with protein misfolding and restore proteostasis both in vitro and in 
vivo. Therefore, molecular chaperones represent important therapeutic targets and their 
manipulation could potentially slow disease progression. A better understanding of 
specialised chaperone functions in neurons will assist in the design of new potential 
therapies based on restoring proteostasis. In addition, it is likely that the study of chaperone 
mutations in disease will provide important insights into how chaperones function in neurons 
and will be important in understanding the specific challenges of neuronal proteostasis. 
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Table 1: Chaperones that combat neurodegeneration related protein misfolding.  
Chapero
ne Family 
Chaperon
e 
Disease/ 
Protein(s) 
Comments 
HSP110 
HSP110 
(HSPH2) 
ALS/SOD1 
Improved vesicle transport deficit in SOD1
G85R
 squid axoplasm 
[67]; with DNAJB1 suppressed polyQ toxicity in flies [68]. 
HD/Htt 
HSP105 
(HSPH1) 
AD/Tau 
HSP105 knock out mouse had increased p-tau and Aβ [69]; 
suppressed aggregation of SOD1
G93A
 in cells [70]. 
ALS/SOD1 
HSP90 
HSP86 
(HSPC1) 
AD/ Aβ 
Reduced Aβ aggregation in vitro [22]; with Hsp60 and Hsp70 
reduced Aβ mitochondrial dysfunction in cells [71]. 
HSP70 
BiP 
(HSPA5) 
AD/ Aβ 
Bound APP and reduced Aβ secretion [72]; reduced polyQ 
aggregation and toxicity in cells [73]; reduced α-synuclein 
toxicity in rat [74]; reduced P23H rhodopsin aggregation and 
photoreceptor cell death [75] [76]. 
HD/Htt 
PD/α-syn 
RP/Rho 
Hsc70 
(HSPA8) 
AD/Tau Binds tau and facilitates microtubule polymerization reducing 
insoluble tau [77] [78] [25]; QBP1 fusion reduced polyQ 
aggregation and toxicity in cells and mice [79], ATPase mutant 
reduced large polyQ aggregates but no effect on toxicity [80], 
reduced axonal transport defect in polyQ fly [81]; binds α-
synuclein and reduced toxicity of fibrils [82] [83]; binding to 
mutant SOD1 [84]. 
HD/Htt 
PD/α-syn 
ALS/SOD1 
Hsp70 
(HSPA1A*) 
AD/ Aβ 
Reduced Aβ aggregation in vitro [22] and in transgenic mice 
[85]; modest effect on R6/2 Htt mice [31] but increased 
aggregation on knock-down in HD flies [86]; suppression of α-
synuclein toxicity in flies [17] cells and mice [16], but another 
report found no effect in mice [87]; reduced mutant SOD1 
aggregation in cells [88] but had no effect in mice [89]; 
suppressed TDP-43 toxicity in fly [90]. 
AD/Tau 
HD/Htt 
PD/α-syn 
ALS/SOD1 
ALS/TDP43 
HSP60 
HSP60 
(HSPD1) 
AD/ Aβ 
Reduced Aβ aggregation in vitro [22] and improved mitochondria 
function in a cell model [71]. 
HSP40/ 
DNAJ 
DNAJA1 
AD/Tau 
Antagonized protective effect of Hsp70 on tau [91]; increased 
polyQ aggregation in some cell models [92]; increase binding of 
Hsp70 to α-synuclein [83]. 
HD/Htt 
PD/α-syn 
DNAJB1 
(Hsp40 or 
AD/ Aβ Reduced Aβ aggregation in vitro with Hsp70 [22]; suppressed 
Htt inclusion formation but did not affect toxicity in cells [93] but 
protective with Hsp110 in flies [68]; increase binding of Hsp70 to 
HD/Htt 
Hdj1) PD/α-syn α-synuclein [83]. 
DNAJB2a 
(HSJ1a) 
HD/Htt 
Reduce polyQ aggregation in vitro, in cells, in mice [37] [39] and 
rats [94]; reduced mutant SOD1 aggregation in cells [48] [45] 
and mice [45]; suppress mutant parkin aggregation and promote 
functional refolding in cells [95] 
ALS/SOD1 
PD/Parkin 
DNAJB6 
AD/ Aβ 
Efficient block of Aβ aggregation in vitro [21]; block polyQ 
aggregation and toxicity in cells and frogs [35] [96].   
HD/Htt 
DNAJB8 HD/Htt block polyQ aggregation and toxicity in cells and frogs [35] [96].  
DNAJC10 RP/Rho Reduced P23H rhodopsin aggregation in cells [97]. 
small HSP 
HSP27 
(HSPB1) 
AD/ Aβ 
Reduced Aβ aggregation in vitro and toxicity on cells [98] and in 
mice [99]; alters tau dynamics in mice [100]; reduced polyQ 
aggregation and toxicity in cells [101] and by viral delivery in rats 
[102] but not transgenic mice [103]; reduced α-synuclein fibril 
formation in vitro [104] and toxicity in cells [105]; reduced SOD1 
aggregation in vitro [41] but small effects in mice [106] [44]. 
AD/Tau 
HD/Htt 
PD/α-syn 
ALS/SOD1 
HSP22 
(HSPB8) 
AD/ Aβ 
Reduced Aβ aggregation in vitro and toxicity on cells [98]; 
reduced polyQ aggregation [32]; Most effective small Hsp at 
reducing α-synuclein fibril formation in vitro [104]; enhanced 
autophagic clearance of SOD1 and TDP-43 [107]. 
HD/Htt 
PD/α-syn 
ALS/SOD1 
ALS/TDP43 
αB-crystallin 
(HSPB5) 
AD/ Aβ 
Reduced Aβ aggregation in vitro and toxicity on cells [98] [108]; 
reduced toxicity of α-synuclein in cells [105]; reduced α-
synuclein fibril formation in vitro [104]; SOD1 aggregation in vitro 
[41] but does not protect in mice [109]. 
PD/α-syn 
ALS/SOD1 
HSP20 
(HSPB6) 
AD/ Aβ Reduced Aβ aggregation in vitro and toxicity on cells [98] [110] 
and in worms [111]; reduced α-synuclein fibril formation in vitro 
[104]. PD/α-syn 
cvHSP 
(HSPB7) 
HD/Htt Most potent small Hsp against polyQ in cell model [32]. 
Co-
chaperone 
CHIP 
AD/Tau 
Reduced tau aggregation in cell [26] and in mice [112]; reduced 
polyQ (ataxin-1) aggregation and toxicity in cells [113]; 
enhanced ubiquitylation of α-synuclein [114]; degradation of 
mutant SOD1 [84]. 
PD/α-syn 
ALS/SOD1 
Cdc37 
AD/Tau 
Regulates tau stability with Bag5 [115]; with Hsp90 in enhanced 
authophagic clearance of TDP-43 [116]. 
ALS/TDP43 
  
 
 
Table 2: Manipulations involving networks of chaperones 
Target Method Animal models showing benefit 
HSF-1 
 
Overexpression or 
constitutively active 
HSF-1 
AD deficits in mice [120]; polyQ in mice [121]; mutant 
SOD1 in mice [122]. 
Knock down or dominant 
negative HSF-1 
Enhanced neurodegeneration in polyQ flies [123]; 
enhanced TDP-43 toxicity in worms [124]. 
Other gene manipulation 
e.g. SIRT1 
SIRT1 mediated suppression of α-synuclein 
aggregation in mice [125]. 
Hsp90 Hsp90 inhibitors e.g. 
Geldanamycin,17-AAG, 
17-DMAG, HSP990, PU-
H71 
Reduction of tau pathology and tau phosphorylation 
in mice [126, 27]; polyQ in flies [123] [127] but in mice 
effect was only temporary due to epigenetic changes 
[128]; SBMA mouse model [129]; SCA3 mouse 
model [130] effective on mutant SOD1 cells but effect 
in mice questionable [131]; α-synuclein toxicity in flies 
[132] [17]; rhodopsin RP in rats [133]. 
Not 
defined 
 
Arimoclomol SOD1 mouse [134] [135] [46]; SBMA mouse model 
[136]; rhodopsin RP [47]. 
Celastrol Mouse model of Aβ [137]; SOD1 mice [138]. 
Geranylgeranylacetone SBMA mice[139]; AD model mice[140]; traumatic 
brain injury[141] 
 
Bag-1 
AD/Tau 
With Hsc70 to target degradation of tau [117]; protects against 
α-synuclein in cells and MPTP in mice [118]. 
PD/α-syn 
Bag-3 ALS/SOD1 
Reduction in polyQ (SCA3) with Hspb8 in cells and flies [119]; 
With HspB8 to stimulate autophagy of SOD1 in cells [107] [34]. 
Bag-5 PD/α-syn Enhanced ubiquitylation of α-synuclein [114]. 
Table 3:  Chaperones mutations identified in neurodegenerative diseases. 
Chaperone 
family 
Chaperone Inheritance Disease Reference 
Hsp70 HSPA9 (Mortalin) Dominant Parkinson’s disease [142,143] 
Hsp60 
HSP60 (HSPD) 
Dominant Spastic paraplegia [144,145] 
Recessive 
Hypomyelinating 
leukodystrophy  
[146] 
CCT4 Recessive 
Hereditary sensory 
neuropathy 
[147] 
CCT5 Recessive 
Sensory neuropathy with 
spastic paraplegia 
[148] 
Hsp40 (DnaJ) 
DNAJB2 (HSJ1) Recessive 
Distal hereditary motor 
neuropathy, 
Charcot Marie Tooth disease 
[48,49] 
DNAJB6 (Mrj) Dominant 
Limb-girdle muscular 
dystrophy 
[149-151] 
DNAJC3 (ERdj6) Recessive 
Diabetes and multisystemic 
neurodegeneration 
[152] 
DNAJC5 (CSPα) Dominant Neuronal ceroid lipofusinosis [153,154] 
DNAJC6 (Auxilin) Recessive Juvenile Parkinsonism [155,156] 
DNAJC13 (RME-8) Dominant Parkinson’s disease [157] 
DNAJC19 (TIM14) Recessive 
Dilated cardiomyopathy and 
cerebellar ataxia 
[158,159] 
DNAJC29 (Sacsin) Recessive 
Spastic ataxia of Charlevoix-
Saguenay 
[160,161] 
Small Hsp 
HSPB1 (Hsp27) 
Dominant 
and 
recessive 
Distal hereditary motor 
neuropathy, 
Charcot Marie Tooth type 2 
[50-56] 
HSPB3 (HspL27) Dominant Hereditary motor neuropathy [162] 
HSPB5 (αβ-crystallin) Recessive Infantile muscular dystrophy [163] 
HSPB8 (Hsp22) Dominant 
Distal hereditary motor 
neuropathy, 
Charcot Marie Tooth disease 
[57] 
Chaperone 
co-factors 
SIL1 Recessive Cerebellar ataxia [164] 
VCP Dominant Amyotrophic lateral sclerosis [165,166] 
BAG3 Dominant 
Muscular dystrophy. 
Giant axonal neuropathy 
[167,168] 
 
 
. 
 
 
Figures 
 
Fig. 1.  HSJ1a acts restore proteostasis for several neurodegeneration proteins. 
Schematic showing the effect of HSJ1a on Htt, SOD1, parkin and tau in neurons. HSJ1a can 
bind to ubiquitylated oligomers of Htt in the nucleus blocking the recruitment of more 
misfolded Htt and further aggregation, leading to increases in soluble Htt and potential 
autophagic clearance of cytoplasmic Htt oligomers [39]. HSJ1 also facilitates proteasomal 
degradation of Htt [37]. HSJ1a blocks the aggregation of mutant parkin and stimulates its 
refolding, so that parkin can function in mitochondrial quality control [95]. In ALS, HSJ1a 
reduces the aggregation of mutant SOD1 and promotes the degradation by proteasome [45]. 
HSJ1a can bind tau, reduce tau phosphorylation and aggregation (Novoselov and Cheetham 
unpublished observations).  
 
